Major network provider goes down ahead of festival
EE posted on social media on Thursday, recognising that the fault was nationwide, but customers in Southwold complained of the issue ahead of the upcoming Latitude festival this weekend.
The broadband network said: "Following a technical fault impacting voice services on our network earlier today, we have now resolved the problem, and the service is running as normal.
"We sincerely apologise and recognise the inconvenience this may have caused."
Customers continued to experience issues on Friday and still had problems making phone calls.
READ MORE: First day of Latitude Festival 2025 kicks off at Henham Park
BT and EE are linked as broadband providers.
A BT spokesperson said: "Following yesterday's technical fault, we are currently experiencing some voice call issues today.
"The impact appears to be less widespread, but we are working to resolve this as soon as possible and sincerely apologise for any inconvenience caused."
Residents in Southwold questioned whether the fault was linked to the upcoming Latitude festival.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
William's homelessness initiative is to deliver homes in third location
The Prince of Wales's Homewards initiative has announced its latest housing project that aims to help eradicate homelessness. A property in south London owned by William's Duchy of Cornwall estate will be converted into 16 flats to provide affordable homes for 18 to 25-year-olds. The new 'Innovative Housing Project' is in the London borough of Lambeth, one of six locations Homewards is working in to create a blueprint to ending homelessness in all its forms, and it will be completed in partnership with homeless charity Centrepoint, which William supports as patron. William marked Homewards's second anniversary this summer by saying his programme was now in 'delivery mode' and the Lambeth initiative is the third Innovative Housing Project to be launched. Seyi Obakin, Centrepoint's chief executive, said: 'Centrepoint is committed to ending youth homelessness in the UK and we know that can only be achieved through collaborative effort. 'We are pleased to work in partnership with Homewards, the Duchy of Cornwall and Lambeth Council to demonstrate that eradicating youth homelessness is achievable. 'By linking rent to individual income levels, this Innovative Housing Project offers more than shelter – it offers young people the stepping stone they need to pursue their careers, build financial resilience and transition out of homelessness for good. 'Through this project, we will demonstrate the effectiveness of this housing model and, hopefully, inspire similar solutions across the country.' The Lambeth project aims to act as a bridge between supported accommodation and the private rented sector with Centrepoint managing the homes and expanding their Independent Living Programme, which aims to break the cycle of homelessness. The flats will be provided to young people already employed, with a number allocated to those moving towards employment, to test a new model to get people into housing and jobs at the same time. With the planning proposal now endorsed by Lambeth Council's planning applications committee, work is expected to begin as soon as possible. Homewards was also involved in the design of the Duchy of Cornwall's first housing project to address homelessness in Nansledan, for which work is already underway. Some 300 homes – a mixture of empty accommodation, private rentals and new builds – are forecast to be delivered through Homewards's Innovative Housing Projects. The first residents moved into flats in Aberdeen in March after Homewards brought together a local housing association, high street retailers and others to provide and furnish the property, and the second Innovative Housing Project, launched in Sheffield. saw tenants move into their new homes in June.
Yahoo
18 minutes ago
- Yahoo
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth
British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 guidance. Driven by exceptional growth in Specialty Medicines and Vaccines, GSK's second-quarter sales reached $10.66 billion (7.98 billion British pounds), a 6% increase at constant currency, exceeding analyst estimates of $10.33 billion. Core earnings jumped 15% at constant currency to $1.24 per share (46.5 pence) outperforming the consensus forecast of $ company attributed this core earnings growth to the strong performance of its Specialty Medicines and Vaccines divisions, coupled with higher royalty income and a disciplined escalation of investment in key research and development (R&D) areas, particularly within Oncology and Vaccines. Vaccine sales jumped 5% (+9% at constant currency or cc) to 2.09 billion pounds, reflecting growth in Meningitis vaccines related to uptake following expanded recommendation and public funding of Bexsero in Europe, as well as growth in Shingrix driven by launch uptake in France and strong demand across several other European markets and Japan. Arexvy sales reached 66 million pounds, up 6% (+13% cc). Meningitis vaccine sales increased 17% (+22% cc) to 379 million, while established vaccine sales of 787 million increased 2% (+6% cc). Shingrix sales reached 853 million pounds, up 3% (+6% cc). In July, the FDA agreed to review the application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 who are at increased risk. Also in July, the FDA extended the review period for the Biologics License Application (BLA) for GSK's Blenrep combinations for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy. View more earnings on GSK Specialty Medicines sales grew by double-digit percentages (+10% and 15% cc) in the quarter to 3.33 billion pounds, reflecting continued growth across disease areas, with strong performances in HIV, Respiratory, Immunology & Inflammation, and Oncology. General Medicines sales fell by 10% (-6% cc) to 2.57 billion pounds. GSK is progressing on 14 major pipeline opportunities, each with a potential value of over 2 billion pounds, set to launch between 2025 and 2031. Phase 3 study for tebipenem, a new antibiotic for complicated urinary tract infections, was stopped early because it worked so well. The company plans to file for approval by the end of the year. Phase 3 development for depemokimab, aimed at treating COPD, has begun with the launch of the ENDURA study program. Key trials expected to begin in the second half of 2025 include GSK'227, a B7H3-targeting antibody-drug conjugate for small cell lung cancer, GSK'981 (IDRx-42) for second-line treatment of gastrointestinal stromal tumors, Efimosfermin for MASH, and an ultra-long-acting injectable HIV treatment combining cabotegravir and rilpivirine, to be given every four months. Tariff Outlook and Guidance Addressing a broader macroeconomic concern, GSK acknowledged the U.S. Administration's initiation of an investigation under Section 232 of the Trade Expansion Act, which seeks to ascertain the potential effects of pharmaceutical product imports on national security. The company said it is well-positioned to respond to the potential financial impact of tariffs, with mitigation options identified. According to Reuters, GSK's CFO indicated an anticipation of some tariffs coming in the second half of the year, which are expected to lower the gross margin slightly. GSK raised its full-year 2025 guidance and says it includes tariffs enacted thus far and the European tariffs indicated this week. It now expects sales to increase toward the top of the 3%–5% range. Core operating profit and earnings are also expected to grow towards the top end of the 6% to 8% range. Specialty Medicine sales are expected to increase in the low teens versus prior guidance of a low double-digit percentage. Vaccine revenue is expected to decline by a low single-digit percent to broadly stable compared to the prior outlook of a decrease of low single-digit percent, and general medicine sales are expected to be broadly stable. Price Action: At last check on Wednesday, GSK stock was up 3.57% to $40.37 during the premarket session. Read Next:Photo by HJBC via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? GSK (GSK): Free Stock Analysis Report This article GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Here's Why Churchill Downs Incorporated (CHDN) Traded Down in Q2
The London Company, an investment management company, released 'The London Company Mid Cap Strategy' second quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities saw a double-digit surge in the second quarter following a sharp decline in the first quarter. The mid-cap composite rose 5.7% (5.5% net) in the second quarter, falling short of the Russell Midcap Index's 8.5% increase. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, The London Company Mid Cap Strategy highlighted stocks such as Churchill Downs Incorporated (NASDAQ:CHDN). Churchill Downs Incorporated (NASDAQ:CHDN) is a US-based racing, online wagering, and gaming entertainment company. The one-month return of Churchill Downs Incorporated (NASDAQ:CHDN) was 5.38%, and its shares lost 22.96% of their value over the last 52 weeks. On July 29, 2025, Churchill Downs Incorporated (NASDAQ:CHDN) stock closed at $110.60 per share, with a market capitalization of $7.756 billion. The London Company Mid Cap Strategy stated the following regarding Churchill Downs Incorporated (NASDAQ:CHDN) in its second quarter 2025 investor letter: "Churchill Downs Incorporated (NASDAQ:CHDN) – CHDN has underperformed due to weakness in regional gaming, concern about consumer spending, and lower Derby profitability y/y. We note that the Derby was facing the 150th anniversary last year, and we continue to like CHDN, its highly cash-generative assets, track record of good capital allocation, and opportunities to reinvest in the business at attractive returns. A city skyline looking down on a busy racetrack with jockeys on horseback. Churchill Downs Incorporated (NASDAQ:CHDN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 39 hedge fund portfolios held Churchill Downs Incorporated (NASDAQ:CHDN) at the end of the first quarter, which was 41 in the previous quarter. In the second quarter of 2025, Churchill Downs Incorporated (NASDAQ:CHDN) delivered all-time record net revenue of $934 million and all-time record adjusted EBITDA of $451 million. While we acknowledge the potential of Churchill Downs Incorporated (NASDAQ:CHDN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Churchill Downs Incorporated (NASDAQ:CHDN) and shared the list of stocks expected to beat the market by 20 percentage points this year. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
